Who
Maher Masoud
President and CEO
Company insider
Files Form 4 as: President and CEO, MaxCyte.
In numbers
- Trades disclosed
- 23
- Buys
- 3
- Sells
- 3
- Bought
- $592K
- Sold
- $923K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Aug 2021
- Last trade
- 27 Mar 2026
- Last filed
- 31 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Mar 2026filed 31 Mar 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 13 Aug 2025filed 13 Aug 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Bought | $103K75,000 at $1.37 | filing |
| 14 Mar 2025filed 18 Mar 2025 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —347,500 at $0.00 | filing |
| 10 Jun 2024filed 10 Jun 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Bought | $345K70,443 at $4.90 | filing |
| 7 Jun 2024filed 10 Jun 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Bought | $144K29,557 at $4.87 | filing |
| 3 Jan 2024filed 4 Jan 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 20 Mar 2023filed 21 Mar 2023 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 25 Mar 2022filed 29 Mar 2022 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —242,000 at $0.00 | filing |
| 16 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —18,562 at $0.00 | filing |
| 16 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code M | $60K18,562 at $3.25 | filing |
| 16 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $224K18,562 at $12.08 | filing |
| 15 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —24,278 at $0.00 | filing |
| 15 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,438 at $0.00 | filing |
| 15 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code M | $50K24,278 at $2.08 | filing |
| 15 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code M | $21K6,438 at $3.25 | filing |
| 15 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $374K30,716 at $12.16 | filing |
| 12 Nov 2021filed 16 Nov 2021 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —25,722 at $0.00 | filing |
News
MaxCyte Sees Preliminary Q3 Core Revenue Of About $8.1 Mln, Raises FY26 Guidance; Shares UpMXCT · rttnews.com · 14 Oct 2026MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceMXCT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Maher Masoud; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.